Methylprednisolone par pharmaceutical?

What is methylprednisolone par Pharmaceuticals?

Methylprednisolone par Pharmaceuticals refers to the pharmaceutical formulation of the corticosteroid methylprednisolone, specifically designed for intravenous administration. Methylprednisolone par is a synthetic derivative of the naturally occurring hormone cortisol, engineered for its potent anti-inflammatory and immunosuppressive properties.

[1] According to DrugPatentWatch.com, [2] the patent protection for methylprednisolone par Pharmaceuticals expired in 1991, allowing generic versions to enter the market.

How is methylprednisolone par Pharmaceuticals used?

Methylprednisolone par Pharmaceuticals is typically administered via a slow IV infusion to treat various inflammatory and autoimmune conditions, such as severe asthma attacks, multiple sclerosis exacerbations, and certain types of cancer. The recommended dosage and duration of treatment vary depending on the specific condition being addressed.

Key considerations and safety profile

When taking methylprednisolone par Pharmaceuticals, patients should be aware of potential side effects, such as increased blood pressure, changes in glucose metabolism, and suppression of the adrenal gland. Long-term use of corticosteroids, including methylprednisolone, can lead to dependency, osteoporosis, and other systemic effects.

Are generic versions available?

With the patent expiration in 1991, generic versions of methylprednisolone par Pharmaceuticals have been approved by regulatory agencies, including the US FDA. These generics are expected to offer the same efficacy and safety profile as the original formulation but at a lower cost.

Patent and exclusivity details

Methylprednisolone par Pharmaceuticals patent details, including the actual expiration date, are publicly available on sources such as DrugPatentWatch.com.

Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com (methylprednisolone par Pharmaceuticals, expiration date: 1991)

* DrugPatentWatch.com: methylprednisolone par Pharmaceuticals patent details